Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer-Reference-Cited by-同舟云学术

Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer

Published:2003-07 Issue:7 Volume:94 Page:606-611
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Oji Yusuke,Miyoshi Yasuo,Koga Satoko,Nakano Yoko,Ando Akiko,Nakatsuka Shin-ichi,Ikeba Ai,Takahashi Eigo,Sakaguchi Nao,Yokota Asumi,Hosen Naoki,Ikegame Kazuhiro,Kawakami Manabu,Tsuboi Akihiro,Oka Yoshihiro,Ogawa Hiroyasu,Aozasa Katsuyuki,Noguchi Shinzaburo,Sugiyama Haruo

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2003.tb01490.x/fullpdf

Reference37 articles.

1. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus

2. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping

3. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour

4. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1.

5. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus.

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overexpression of WT1 in all molecular subtypes of breast cancer and its impact on survival: exploring oncogenic and tumor suppressor roles of distinct WT1 isoforms;Molecular Biology Reports;2024-04-20

2. WT1 as a myoepithelial marker: a comparative study of breast, cutaneous, and salivary gland lesions;Human Pathology;2023-05

3. BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma;Journal of Translational Medicine;2022-02-05

4. Long Noncoding RNA WT1-AS Inhibits the Progression of Cervical Cancer by Sponging miR-205;Cancer Biotherapy and Radiopharmaceuticals;2021-08-01

5. Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia;Expert Opinion on Investigational Drugs;2021-05-31